1 In this study the renal selectivity of dopamine and its prodrugs L-dopa and gludopa, with respect to their effects on regional blood flow, vascular resistance and central haemodynamics was investigated in normal rats and in rats with glycerol-induced acute renal failure (ARF). 2 In normal, anaesthetized rats, dopamine as well as its prodrugs caused a dose-dependent reduction of vascular resistance in the kidney (RR), mesentery (MR) and hindquarters (HQR) (dose range: dopamine: 0. 1-5 ftmol kg-' h-i; L-dopa and gludopa: 1 -200 pmol kg'-h-'). Blood pressure and heart rate were affected at the highest dose only. 3 Administration of glycerol induced a preferential renal vasoconstriction; renal blood flow (-60%) and vascular resistance (+ 190%) were significantly more affected than MR (+40%) and HQR (+ 60%). This was only ameliorated by a low rate (10 pmol kg-' h-') infusion of gludopa: the glycerolinduced reduction of renal flow and increase in RR were significantly attenuated. A high dose of gludopa (100 gmol kg-' h-') or any dose of L-dopa or dopamine did not induce this beneficial effect. The glycerol-induced increase in MR and HQR was not attenuated by any of the treatments used. 4 The results indicate that gludopa is not renally selective at a pharmacodynamic level in normal, anaesthetized rats. Contrary to this, a low dose of gludopa does cause a renal selective vasodilatation and reduction of RR in rats with glycerol-induced ARF. This difference could be explained by a difference in renal vascular tone between normal rats and glycerol-induced ARF rats. A high dose of gludopa does not cause these renal-selective effects: renal resistance and renal flow are at the same level as following glycerol and saline. This is probably due to the systemic effects of the released dopamine.
Introduction
Gludopa is a prodrug of dopamine (Wilk et al., 1978) . It is converted by y-glutamyl transpeptidase to L-dopa and subsequently by aromatic aminoacid decarboxylase to dopamine. This metabolism occurs predominantly in the kidney (Barthelmebs et al., 1990; Boateng et al., 1990; Cummings et al., 1990) . The effects of gludopa on the kidney have been described by several investigators in normal rats (Wilk et al., 1978; , rats with decreased renal function (Casson et al., 1982; 1983; Boateng et al., 1990; Barthelmebs et al., 1991) , rabbit (Wang, Z.-Q. et al., 1992) and man (Jeffrey et al., 1988a; Casagrande et al., 1989; MacDonald et al., 1989) . Based on these results it was concluded that gludopa is a kidney-specific dopamine precursor and has kidney-selective actions. This selectivity was defined by comparison of renal actions with effects on heart and blood pressure, but no comparison has been made with other vascular regions, except for hindlimb flow in the conscious rabbit (Wang, Z-Q. et al., 1992) : it was found that gludopa has renal effects at doses that do not change hindlimb flow.
Other y-glutamyl derived renal selective prodrugs are for instance N-acetyl-'y-glutamyl sulphamethoxazole (Orlowski et al., 1980; Drieman et al., 1990a) , the renal vasodilator CGP 22979 (Smits & Struijker Boudier, 1985) and the dopamine-phydroxylase inhibitor prodrug, SC-47792 (Koepke et al., 1991) . The selectivity of these prodrugs is determined in part by the presence of a transport system for the prodrug in the kidney and of intracellular converting enzymes (Drieman et al., 1990a,b; Hwang & Elfarra, 1991) . N-acetyl-y-glutamyl prodrugs are handled this way by the kidney, unlike yglutamyl prodrugs, which are converted extracellularly and cause relatively high plasma concentrations of active drug, released through the action of the extracellular enzyme yglutamyl transpeptidase (Drieman et al., 1990a; . As gludopa is not an acetylated prodrug, it is likely that the dopamine released from gludopa is also systemically available. This led us to investigate the selectivity of gludopa with respect to different vascular regions in the rat.
The second question investigated in this study is whether the protective effects of gludopa on the kidney in the glycerol-treated rat model of acute renal failure (ARF), as has been described by Casson et al. (1982 Casson et al. ( , 1983 , is due exclusively to local renal effects of gludopa or also to systemic effects. The decreased glomerular filtration rate in this model of ARF is associated with preglomerular vasoconstriction (Hsu et al., 1979; Wolfert & Oken, 1989) . Dopamine increases renal plasma flow and glomerular filtration rate through DA, receptor stimulation in efferent and afferent arteries (see for review e.g. Lee, 1982; Felder et al., 1989) . Furthermore, DA, receptor stimulation results in normalization of the glomerular filtration rate (GFR) in a state of hyperfiltration caused by glycine (Wang Y.W. et al., 1992) or streptozotocin-induced diabetes (Barthelmebs et al., 1991 In all experiments, miniaturized Doppler flowprobes were implanted on the left renal artery, superior mesenteric artery and abdominal aorta of the rats under pentobarbitone anaesthesia (50mgkg-', i.p.), as described by Smits & Struyker Boudier (1985) . Doppler flow probes record changes in blood flow; therefore only relative and not absolute blood flows are recorded. The animals were provided with polyethylene catheters for infusion of pentobarbitone and drugs in both femoral veins, and in the abdominal aorta via the left femoral artery for blood pressure measurements. The body temperature of the rats was kept constant at 37TC.
Anaesthesia was maintained by a constant rate infusion of pentobarbitone (24 mg kg-' h-l). Following stabilization, mean arterial pressure (MAP), systolic pressure (SP), heart rate (HR) and the relative blood flows through the left renal artery (renal flow: RF), superior mesenteric artery (mesenteric flow: MF) and abdominal aorta (hindquarter flow: HQF) were recorded. (Finckh, 1957; Carrol et al., 1965; Casson et al., 1983) . The effect of glycerol-induced ARF on haemodynamic parameters and regional blood flows was studied as follows. Rats, instrumented as described above, were infused with pentobarbitone (24mgkg-'h-'; 2.5mlkg-'h-') and saline (2.5 ml kg-' h-'). A pilot experiment showed that the rate of total saline infusion was important: when the rate was reduced by 50% most of the animals did not survive for 4 h; a higher (200%) rate of infusion had a too large protective effect on the kidneys, as has been described for conscious rats (Casson et al., 1982; Cushner et al., 1986) . For the same reason, the rats were not dehydrated 24 h prior to induction of ARF. After the rats were stable for about 30 min, glycerol was injected s.c. (t = 0) and all parameters were recorded for 4 h. Changes in blood flow and vascular resistance are expressed as percentage change at t = 4 h (average of the last 15 min of these 4 h) compared to control period at t= -15 min to t =0, changes in the other haemodynamic parameters in absolute differences (beats per min (b.p.m.) and mmHg).
Effects of dopamine and dopamine prodrugs on ARF Experiments were conducted as described above, except that at t = -30 min (i.e. 30 min before glycerol injection, which is t = 0), a continuous infusion of dopamine (0.5 and 5 lmol kg-' h-'), L-dopa (10 and l 00 mol kg-' h'-) or gludopa (10 and 100 ptmol kg' h-') in saline was started instead of the saline infusion; total infusion rate (5 ml kg-' h') was the same in all experiments. Changes in parameters measured at t = 4 h (average of the last 15 min of these 4 h) are compared to the drug infusion control period (t = -15 min to t = 0). 
Statistics
Data are presented as mean ± s.e. Groups were compared by one-way analysis of variance, followed by Duncan's range test. Differences were considered to be statistically significant when P<0.05.
Results
Effects of dopamine, L-dopa and gludopa on regional The effects of dopamine and L-dopa on MAP, SP and HR were similar: no effects in low doses and a significant rise of all parameters at high doses (Figures la and 2a) . At the high dose of 200 Amolkg-'h-' gludopa caused an increase in systolic pressure, but not in HR or MAP (Figure 3a) .
These results indicate that dopamine and its prodrugs Ldopa and gludopa are not renal-selective at low doses in the rat, but that all resistances measured decrease at a dose which does not affect heart rate or blood pressure. Based on the results of these experiments, we chose to use doses of gludopa, L-dopa and dopamine in the ARF studies that decreased RR, MR and HQR without affecting blood pressure and heart rate, and higher doses which do affect these parameters.
Glycerol-induced ARF
The administration of glycerol had the following effects. (Figure 4b and 4c ), nor were MAP, SP or HR significantly different from control ( Figure  4a ). Unlike the saline control it was found that not only RF, but also HQF was significantly lower than MF. Most of the glycerol-treated animals did not survive the high dose (5 gmol kg-' h-1 dopamine) for 4 h.
L-dopa at a low dose (10fLmol kg-' h-') caused effects comparable to dopamine (0.5 ymol kg' h'). The (Casson et al., 1983; Barthelmebs et al., 1991; Brooks et al., 1991; Wang, Y.-W. et al., 1992) . Hence, a renal selective dopamine prodrug, without systemic side-effects, would be of great therapeutic value.
Gludopa has been described as renal selective in mice, rat and man (e.g. Wilk et al., 1978; Lee, 1987; Jeffrey et al., 1988a,b; MacDonald et al., 1989; Cummings et al., 1990) . Dopamine concentrations following gludopa administration were found to be much higher in the kidney than in mouse heart (Wilk et al., 1978) or rat liver (Cummings et al., 1990) . Furthermore, in rats it was found that renal plasma flow increased more following gludopa compared to dopamine and L-dopa at a dose at which no cardiac responses were observed (Wilk et al., 1979) . Our results show however, that in normal, anaesthetized rats, gludopa does not cause a renal selective increase in blood flow; mesenteric and hindquarter flow were increased to the same extent. This is in contrast with the findings in the conscious rabbit, where no increase in hindquarter flow was found after gludopa (Wang, Z.-Q. et al., 1992) . Species differences in receptor sensitivity or abundance, as well as differences between the state of consciousness may underlie this difference. Since blood pressure was not decreased, our results indicate that cardiac output must have been increased. This can be due to baroreflex activation, but a direct cardiac action of dopamine may also be involved.
The lack of renal selectivity of gludopa implies that the dopamine, released from gludopa is systemically available. Pharmacokinetic studies with gludopa in the rat support our pharmacodynamic findings. After a bolus injection of gludopa, considerable amounts of L-dopa and dopamine were found in plasma (Boateng et al., 1990; Cummings et al., 1990) . Due to the short halflife time of dopamine, it is difficult to estimate the amount of dopamine that is available systemically in vivo. In vitro in rat isolated kidney it was found that the rate of dopamine release from gludopa to the perfusate was about 3 times higher than to the urine (Barthelmebs et al., 1990) . This high leakage from the kidney is proably due to the nature of the prodrug. Gludopa is the y-glutamyl prodrug of L-dopa. We have found with the model prodrugs 7y-glutamyl sulphamethoxazole and N-acetyly-glutamyl sulphamethoxazole that the N-acetyl group is essential for high kidney-selectivity: the site of conversion is intracellular in the latter case, unlike that of the y-glutamyl prodrug (Drieman et al., 1990a) . Sulphamethoxazole, released intracellularly, is retained by the kidney, whereas extracellularly released drug causes relatively high plasma concentrations. It would therefore be very interesting to study the N-acetyl derivative of gludopa with respect to its renal selectivity. Casson et al. (1983) did, however, report that gludopa has a protective effect on the glycerol-treated rat model of ARF. In the present study we investigated whether this protective effect is due to local or systemic dopamine effects. We chose to do this in the early phases of the induction of ARF, because it has been suggested that maintenance of renal blood flow during the first hours after glycerol administration protects the kidney from ARF (Cushner et al., 1986) .
Our results show that glycerol decreases renal blood flow significantly more than mesenteric flow or hindlimb flow (Figure 4c ). This decrease was ameliorated only by a continuous infusion of gludopa at a low rate. Gludopa at a high rate reversed this beneficial effect, which indicates that the systemic effects of dopamine (on adrenoceptors) counteract the local beneficial effects of dopamine. The effects of the low dose gludopa on renal blood flow, in combination with the finding of Casson et al. (1983) that gludopa protects from ARF, confirm the suggestion of Cushner et al. (1986) that preservation of the renal blood flow may cause a reduction or prevention of ARF.
The dose of gludopa was not adjusted to the decreased kidney function, since the pharmacokinetics of gludopa are not changed in rats with glycerol-induced ARF (Boateng et al., 1990) . The renal effects of gludopa in glycerol-induced ARF in rats are different from those in normal rats. This could be caused by the difference in vascular diameter in these situations. When the diameter is near maximal, a dopamine-induced arteriolar vasodilatation will not result in a significant decrease of renal resistance, whereas when the renal vessels are contracted, a dilatation will have large effects on the resistance.
The pharmacokinetic studies combined with the pharmacodynamic studies lead to the conclusion that although gludopa may cause relatively high renal concentrations of dopamine, it does not seem to be kidney-selective under physiological circumstances. In pathological circumstances, on the other hand, gludopa has beneficial effects on the kidney (Casson et al., 1983; Barthelmebs et al., 1991) . This does not seem to be due to systemic dopamine effects, as dopamine and L-dopa did not increase kidney function. Local stimulation of DI receptors in the kidney is supposed to be responsible for this effect: fenoldopam ameliorated kidney function in amphotericin B nephrotoxicity in dogs (Brooks et al., 1991) , and glycine-induced hyperfiltration (Wang, Y.-W. et al., 1992) and hyperfiltration caused by streptozotocin-induced diabetes (Barthelmebs et al., 1991) in the rat. In the latter two models fenoldopam and gludopa decrease filtration fraction, thus counteracting the existing hyperfiltration. This decrease in filtration fraction is caused by preferential efferent arteriolar vasodilatation, causing an increase in renal blood flow, a decrease in renal vascular resistance and little effect on glomerular filtration rate (Wang, Y.-W. et al., 1992) . The restoration or potentiation of the tubuloglomerular feedback mechanism by dopamine probably plays a significant role in the reversal of hyperfiltration in these models (Premen, 1988; Schnermann et al., 1990) .
In consious rats, gludopa reverses the polyuria caused by glycerol, but has no effect on urine production in normal rats (Casson et al., 1982; 1983) . This is consistent with the mechanism described above and with our results: no renal selective blood flow increase in normal rats but a renal selective attenuation of the glycerol-induced fall in renal flow.
The dose of gludopa should not be too high in order to avoid systemic effects that counteract the beneficial renal effects. A more renal selective prodrug of dopamine would have a higher therapeutic index. N-acetyl gludopa is in our opinion an interesting candidate, considering the effects of gludopa itself and the beneficial effects of an N-acetyl group on the renal selectivity of prodrugs (Drieman et al., 1990a; . An alternative would be a renal selective D1 agonist. Such a compound might become a useful therapeutic agent, for instance in protecting patients against the nephrotoxic side effects of cytostatics.
